Literature DB >> 23716468

Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.

Brent S Pedersen1, Panagiotis A Konstantinopoulos, Monique A Spillman, Subhajyoti De.   

Abstract

Loss of heterozygosity (LOH) is a common type of genomic alterations in ovarian cancer. Analyzing 74,415 copy neutral LOH events in 513 serous ovarian adenocarcinomas samples from the Cancer Genome Atlas, we report that the frequency of LOH events increases with age. Similar trend is observed for LOH involving chromosome 17, which is frequently implicated in ovarian cancer. The results are consistent when we analyze data from the Boston high-grade serous cancer cohort. We further show that germ line and somatic mutations in BRCA1 (in chromosome 17) and BRCA2 (in chromosome 13) loci are not necessary to establish the pattern. We also report significant age-related changes in expression patterns for several genes in the homologous recombination (HR) pathway, such as BRCA1, RAD50, RAD52, XRCC2, XRCC3, and MRE11A in these patient samples. Furthermore, we develop a metric for pathway-level imbalance, and show that increased imbalance in the HR pathway, i.e., increase in expression of some HR genes and decrease in expression of others, is common and correlates significantly with the frequency of LOH events in the patient samples. Taken together, it is highly likely that aging and deregulation of HR pathway contribute to the increased incidence of copy-neutral LOH in ovarian cancer patients.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716468      PMCID: PMC3767172          DOI: 10.1002/gcc.22075

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  33 in total

Review 1.  Antineoplastic chemotherapy of the older cancer patient.

Authors:  L Balducci; M B Corcoran
Journal:  Hematol Oncol Clin North Am       Date:  2000-02       Impact factor: 3.722

2.  Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation.

Authors:  A Garcia; E Bussaglia; P Machin; X Matias-Guiu; J Prat
Journal:  Int J Gynecol Pathol       Date:  2000-04       Impact factor: 2.762

3.  Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.

Authors:  Heidi Schwarzenbach; Corinna Eichelser; Jolanthe Kropidlowski; Wolfgang Janni; Brigitte Rack; Klaus Pantel
Journal:  Clin Cancer Res       Date:  2012-09-25       Impact factor: 12.531

4.  Increased incidence of brain metastases in BRCA1-related ovarian cancers.

Authors:  Masayuki Sekine; Kosuke Yoshihara; Dai Komata; Kazufumi Haino; Koji Nishino; Kenichi Tanaka
Journal:  J Obstet Gynaecol Res       Date:  2012-08-13       Impact factor: 1.730

5.  Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans.

Authors:  Shiny Titus; Fang Li; Robert Stobezki; Komala Akula; Evrim Unsal; Kyungah Jeong; Maura Dickler; Mark Robson; Fred Moy; Sumanta Goswami; Kutluk Oktay
Journal:  Sci Transl Med       Date:  2013-02-13       Impact factor: 17.956

6.  Rising ovarian cancer mortality in the elderly: a manifestation of differential survival.

Authors:  J E Riggs
Journal:  Gynecol Oncol       Date:  1995-07       Impact factor: 5.482

Review 7.  Telomeres, cancer & aging: live long & prosper?

Authors:  Joel C Eissenberg
Journal:  Mo Med       Date:  2013 Jan-Feb

8.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

9.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.

Authors:  Elise Ruark; Katie Snape; Peter Humburg; Chey Loveday; Ilirjana Bajrami; Rachel Brough; Daniel Nava Rodrigues; Anthony Renwick; Sheila Seal; Emma Ramsay; Silvana Del Vecchio Duarte; Manuel A Rivas; Margaret Warren-Perry; Anna Zachariou; Adriana Campion-Flora; Sandra Hanks; Anne Murray; Naser Ansari Pour; Jenny Douglas; Lorna Gregory; Andrew Rimmer; Neil M Walker; Tsun-Po Yang; Julian W Adlard; Julian Barwell; Jonathan Berg; Angela F Brady; Carole Brewer; Glen Brice; Cyril Chapman; Jackie Cook; Rosemarie Davidson; Alan Donaldson; Fiona Douglas; Diana Eccles; D Gareth Evans; Lynn Greenhalgh; Alex Henderson; Louise Izatt; Ajith Kumar; Fiona Lalloo; Zosia Miedzybrodzka; Patrick J Morrison; Joan Paterson; Mary Porteous; Mark T Rogers; Susan Shanley; Lisa Walker; Martin Gore; Richard Houlston; Matthew A Brown; Mark J Caufield; Panagiotis Deloukas; Mark I McCarthy; John A Todd; Clare Turnbull; Jorge S Reis-Filho; Alan Ashworth; Antonis C Antoniou; Christopher J Lord; Peter Donnelly; Nazneen Rahman
Journal:  Nature       Date:  2012-12-16       Impact factor: 49.962

Review 10.  DNA damage, cellular senescence and organismal ageing: causal or correlative?

Authors:  Jian-Hua Chen; C Nicholes Hales; Susan E Ozanne
Journal:  Nucleic Acids Res       Date:  2007-10-02       Impact factor: 16.971

View more
  12 in total

Review 1.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

2.  Impacts of somatic mutations on gene expression: an association perspective.

Authors:  Peilin Jia; Zhongming Zhao
Journal:  Brief Bioinform       Date:  2017-05-01       Impact factor: 11.622

3.  Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patients.

Authors:  Leila Aghili; Jasmine Foo; James DeGregori; Subhajyoti De
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

4.  sCNAphase: using haplotype resolved read depth to genotype somatic copy number alterations from low cellularity aneuploid tumors.

Authors:  Wenhan Chen; Alan J Robertson; Devika Ganesamoorthy; Lachlan J M Coin
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

5.  Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response.

Authors:  Yogesh Kumar; Jianfeng Yang; Taobo Hu; Lei Chen; Zhi Xu; Lin Xu; Xiao-Xia Hu; Gusheng Tang; Jian-Min Wang; Yi Li; Wai-Sang Poon; Weiqing Wan; Liwei Zhang; Wai-Kin Mat; Frank W Pun; Peggy Lee; Timothy H Y Cheong; Xiaofan Ding; Siu-Kin Ng; Shui-Ying Tsang; Jin-Fei Chen; Peng Zhang; Shao Li; Hong-Yang Wang; Hong Xue
Journal:  BMC Med Genomics       Date:  2015-07-25       Impact factor: 3.063

6.  Loss of heterozygosity preferentially occurs in early replicating regions in cancer genomes.

Authors:  Brent S Pedersen; Subhajyoti De
Journal:  Nucleic Acids Res       Date:  2013-06-22       Impact factor: 16.971

7.  Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.

Authors:  Musaffe Tuna; Zhenlin Ju; Marcel Smid; Christopher I Amos; Gordon B Mills
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

8.  Role of NSC319726 in ovarian cancer based on the bioinformatics analyses.

Authors:  Ji Xue; Guang Yang; Hong Ding; Pu Wang; Changhong Wang
Journal:  Onco Targets Ther       Date:  2015-12-15       Impact factor: 4.147

9.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann
Journal:  Lancet       Date:  2017-09-12       Impact factor: 79.321

10.  Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.

Authors:  Cunzhong Yuan; Xiaoyan Liu; Shi Yan; Cunfang Wang; Beihua Kong
Journal:  Biomed Res Int       Date:  2014-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.